{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T16:14:28Z","timestamp":1779898468172,"version":"3.53.1"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,5,27]],"date-time":"2021-05-27T00:00:00Z","timestamp":1622073600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,5,27]],"date-time":"2021-05-27T00:00:00Z","timestamp":1622073600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100010665","name":"H2020 Marie Sk\u0142odowska-Curie Actions","doi-asserted-by":"publisher","award":["764458"],"award-info":[{"award-number":["764458"]}],"id":[{"id":"10.13039\/100010665","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["EJNMMI Res"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>[<jats:sup>18<\/jats:sup>F]MK-6240 is a PET tracer with sub-nanomolar affinity for neurofibrillary tangles. Therefore, tau quantification is possible with [<jats:sup>18<\/jats:sup>F]MK-6240 PET\/CT scans, and it can be used for assessment of Alzheimer\u2019s disease. However, long acquisition scans are required to provide fully quantitative estimates of pharmacokinetic parameters. Therefore, on the present study, dual-time-window (DTW) acquisitions was simulated to reduce PET\/CT acquisition time, while taking into consideration perfusion changes and possible scanning protocol non-compliance. To that end, time activity curves (TACs) representing a 120-min acquisition (TAC<jats:sub>120<\/jats:sub>) were simulated using a two-tissue compartment model with metabolite corrected arterial input function from 90-min dynamic [<jats:sup>18<\/jats:sup>F]MK-6240 PET scans of three healthy control subjects and five subjects with mild cognitive impairment or Alzheimer\u2019s disease. Therefore, TACs corresponding to different levels of specific binding were generated and then various perfusion changes were simulated. Next, DTW acquisitions were simulated consisting of an acquisition starting at tracer injection, a break and a second acquisition starting at 90\u00a0min post-injection. Finally, non-compliance with the PET\/CT scanning protocol were simulated to assess its impact on quantification. All TACs were quantified using reference Logan\u2019s distribution volume ratio (DVR) and standardized uptake value ratio (SUVR<jats:sub>90<\/jats:sub>) using the cerebellar cortex as reference region.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>It was found that DVR from a DTW protocol with a 60-min break between two 30-min dynamic scans closely approximates the DVR from the uninterrupted TAC<jats:sub>120<\/jats:sub>, with a regional bias smaller than 2.5%. Moreover, SUVR<jats:sub>90<\/jats:sub> estimates were more susceptible (regional bias\u2009\u2264\u200919%) to changes in perfusion compared to DVR from a DTW TAC (regional bias\u2009\u2264\u200910%). Similarly, SUVR<jats:sub>90<\/jats:sub> was affected by late-time scanning protocol delays reaching an increase of 8% for a 20-min delay, while DVR was not affected (regional bias\u2009&lt;\u20091.5%) by DTW protocol non-compliance.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Therefore, such DTW protocol has the potential to increase patient comfort and throughput without compromising quantitative accuracy and is more reliable against SUVR in terms of perfusion changes and protocol deviations, which could prove beneficial for drug effect assessment and patient follow-up using longitudinal [<jats:sup>18<\/jats:sup>F]MK-6240 PET imaging.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13550-021-00790-x","type":"journal-article","created":{"date-parts":[[2021,5,27]],"date-time":"2021-05-27T20:11:25Z","timestamp":1622146285000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["A dual-time-window protocol to reduce acquisition time of dynamic tau PET imaging using [18F]MK-6240"],"prefix":"10.1186","volume":"11","author":[{"given":"Guilherme D.","family":"Kolinger","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"V\u00e1llez Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Talakad G.","family":"Lohith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric D.","family":"Hostetler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cyrille","family":"Sur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arie","family":"Struyk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald","family":"Boellaard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5862-640X","authenticated-orcid":false,"given":"Michel","family":"Koole","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,5,27]]},"reference":[{"issue":"1","key":"790_CR1","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/S1474-4422(14)70252-2","volume":"14","author":"VL Villemagne","year":"2015","unstructured":"Villemagne VL, Fodero-Tavoletti MT, Masters CL, Rowe CC. Tau imaging: early progress and future directions. Lancet Neurol. 2015;14(1):114\u201324.","journal-title":"Lancet Neurol"},{"issue":"4","key":"790_CR2","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1007\/BF00308809","volume":"82","author":"H Braak","year":"1991","unstructured":"Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol (Berl). 1991;82(4):239\u201359.","journal-title":"Acta Neuropathol (Berl)"},{"issue":"1","key":"790_CR3","doi-asserted-by":"publisher","first-page":"93","DOI":"10.2967\/jnumed.118.209650","volume":"60","author":"TJ Betthauser","year":"2019","unstructured":"Betthauser TJ, Cody KA, Zammit MD, Murali D, Converse AK, Barnhart TE, et al. In vivo characterization and quantification of neurofibrillary tau PET radioligand 18 F-MK-6240 in humans from alzheimer disease dementia to young controls. J Nucl Med. 2019;60(1):93\u20139.","journal-title":"J Nucl Med"},{"issue":"1","key":"790_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13195-018-0402-y","volume":"10","author":"TA Pascoal","year":"2018","unstructured":"Pascoal TA, Shin M, Kang MS, Chamoun M, Chartrand D, Mathotaarachchi S, et al. In vivo quantification of neurofibrillary tangles with [18 F]MK-6240. Alzheimers Res Ther. 2018;10(1):1\u201314.","journal-title":"Alzheimers Res Ther"},{"issue":"10","key":"790_CR5","doi-asserted-by":"publisher","first-page":"2099","DOI":"10.1007\/s00259-019-04419-z","volume":"46","author":"NJ Guehl","year":"2019","unstructured":"Guehl NJ, Wooten DW, Yokell DL, Moon S-H, Dhaynaut M, Katz S, et al. Evaluation of pharmacokinetic modeling strategies for in-vivo quantification of tau with the radiotracer [18F]MK6240 in human subjects. Eur J Nucl Med Mol Imaging. 2019;46(10):2099\u2013111.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"790_CR6","doi-asserted-by":"publisher","first-page":"107","DOI":"10.2967\/jnumed.118.208215","volume":"60","author":"TG Lohith","year":"2019","unstructured":"Lohith TG, Bennacef I, Vandenberghe R, Vandenbulcke M, Salinas CA, Declercq R, et al. Brain imaging of alzheimer dementia patients and elderly controls with 18F-MK-6240, a PET tracer targeting neurofibrillary tangles. J Nucl Med. 2019;60(1):107\u201314.","journal-title":"J Nucl Med"},{"key":"790_CR7","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awaa180\/5872095","author":"TA Pascoal","year":"2020","unstructured":"Pascoal TA, Therriault J, Benedet AL, Savard M, Lussier FZ, Chamoun M, et al. 18F-MK-6240 PET for early and late detection of neurofibrillary tangles. Brain. 2020. https:\/\/doi.org\/10.1093\/brain\/awaa180\/5872095.","journal-title":"Brain"},{"issue":"15","key":"790_CR8","doi-asserted-by":"publisher","first-page":"1186","DOI":"10.1212\/WNL.0b013e3181bacf1b","volume":"73","author":"NM Scheinin","year":"2009","unstructured":"Scheinin NM, Aalto S, Koikkalainen J, Lotjonen J, Karrasch M, Kemppainen N, et al. Follow-up of [11C]PIB uptake and brain volume in patients with Alzheimer disease and controls. Neurology. 2009;73(15):1186\u201392.","journal-title":"Neurology"},{"issue":"9","key":"790_CR9","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.2967\/jnumed.112.113654","volume":"54","author":"BNM Van Berckel","year":"2013","unstructured":"Van Berckel BNM, Ossenkoppele R, Tolboom N, Yaqub M, Foster-Dingley JC, Windhorst AD, et al. Longitudinal amyloid imaging using 11C-PiB: methodologic considerations. J Nucl Med. 2013;54(9):1570\u20136.","journal-title":"J Nucl Med"},{"issue":"7","key":"790_CR10","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.2967\/jnumed.116.188029","volume":"58","author":"AA Lammertsma","year":"2017","unstructured":"Lammertsma AA. Forward to the past: the case for quantitative PET imaging. J Nucl Med. 2017;58(7):1019\u201324.","journal-title":"J Nucl Med"},{"key":"790_CR11","doi-asserted-by":"crossref","unstructured":"Jovalekic A, Koglin N, Mueller A, Stephens AW. New protein deposition tracers in the pipeline. EJNMMI Radiopharm Chem. 2017;1(1):11.","DOI":"10.1186\/s41181-016-0015-3"},{"issue":"10","key":"790_CR12","doi-asserted-by":"publisher","first-page":"4778","DOI":"10.1021\/acs.jmedchem.6b00166","volume":"59","author":"AM Walji","year":"2016","unstructured":"Walji AM, Hostetler ED, Selnick H, Zeng Z, Miller P, Bennacef I, et al. Discovery of 6-(Fluoro-18F)-3-(1H-pyrrolo[2,3-c]pyridin-1-yl)isoquinolin-5-amine ([18F]-MK-6240): a positron emission tomography (PET) imaging agent for quantification of neurofibrillary tangles (NFTs). J Med Chem. 2016;59(10):4778\u201389.","journal-title":"J Med Chem"},{"key":"790_CR13","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-020-04831-w","author":"D Visser","year":"2020","unstructured":"Visser D, Wolters EE, Verfaillie SCJ, Coomans EM, Timmers T, Tuncel H, et al. Tau pathology and relative cerebral blood flow are independently associated with cognition in Alzheimer\u2019s disease. Eur J Nucl Med Mol Imaging. 2020. https:\/\/doi.org\/10.1007\/s00259-020-04831-w.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"790_CR14","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/s13550-019-0499-4","volume":"9","author":"F Heeman","year":"2019","unstructured":"Heeman F, Yaqub M, Lopes Alves I, Heurling K, Berkhof J, Gispert JD, et al. Optimized dual-time-window protocols for quantitative [18F]flutemetamol and [18F]florbetaben PET studies. EJNMMI Res. 2019;9(1):32.","journal-title":"EJNMMI Res"},{"key":"790_CR15","doi-asserted-by":"crossref","unstructured":"Heeman F, Yaqub M, Lopes Alves I, Heurling K, Bullich S, Gispert JD, et al. Simulating the effect of cerebral blood flow changes on regional quantification of [18F]flutemetamol and [18F]florbetaben studies. J Cereb Blood Flow Metab. 2021;41(3):579\u2013589.","DOI":"10.1177\/0271678X20918029"},{"key":"790_CR16","unstructured":"Gaser C, Dahnke R, Kurth K, Luders E. A Computational anatomy toolbox for the analysis of structural MRI data. NeuroImage. in review."},{"issue":"3","key":"790_CR17","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1016\/j.neuroimage.2005.02.018","volume":"26","author":"J Ashburner","year":"2005","unstructured":"Ashburner J, Friston KJ. Unified segmentation. Neuroimage. 2005;26(3):839\u201351.","journal-title":"Neuroimage"},{"key":"790_CR18","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1007\/978-3-540-30135-6_91","volume-title":"Medical Image Computing and Computer-Assisted Intervention\u2014MICCAI 2004","author":"E D\u2019Agostino","year":"2004","unstructured":"D\u2019Agostino E, Maes F, Vandermeulen D, Suetens P. Non-rigid atlas-to-image registration by minimization of class-conditional image entropy. In: Barillot C, Haynor DR, Hellier P, editors. Medical Image Computing and Computer-Assisted Intervention\u2014MICCAI 2004. Berlin: Springer; 2004. p. 745\u201353. https:\/\/doi.org\/10.1007\/978-3-540-30135-6_91."},{"issue":"4","key":"790_CR19","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1002\/hbm.10123","volume":"19","author":"A Hammers","year":"2003","unstructured":"Hammers A, Allom R, Koepp MJ, Free SL, Myers R, Lemieux L, et al. Three-dimensional maximum probability atlas of the human brain, with particular reference to the temporal lobe. Hum Brain Mapp. 2003;19(4):224\u201347.","journal-title":"Hum Brain Mapp"},{"key":"790_CR20","first-page":"1","volume":"2014","author":"M Wang","year":"2014","unstructured":"Wang M. Generalized estimating equations in longitudinal data analysis: a review and recent developments. Adv Stat. 2014;2014:1\u201311.","journal-title":"Adv Stat"},{"issue":"1","key":"790_CR21","doi-asserted-by":"publisher","first-page":"121","DOI":"10.2307\/2531248","volume":"42","author":"SL Zeger","year":"1986","unstructured":"Zeger SL, Liang K-Y. Longitudinal data analysis for discrete and continuous outcomes. Biometrics. 1986;42(1):121.","journal-title":"Biometrics"},{"issue":"1","key":"790_CR22","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1097\/AAP.0b013e31823ebc74","volume":"37","author":"Y Ma","year":"2012","unstructured":"Ma Y, Mazumdar M, Memtsoudis SG. Beyond repeated-measures analysis of variance: advanced statistical methods for the analysis of longitudinal data in anesthesia research. Reg Anesth Pain Med. 2012;37(1):99\u2013105.","journal-title":"Reg Anesth Pain Med"},{"issue":"11","key":"790_CR23","doi-asserted-by":"publisher","first-page":"2172","DOI":"10.1177\/0271678X18783628","volume":"39","author":"SS Golla","year":"2019","unstructured":"Golla SS, Verfaillie SC, Boellaard R, Adriaanse SM, Zwan MD, Schuit RC, et al. Quantification of [18F]florbetapir: a test\u2013retest tracer kinetic modelling study. J Cereb Blood Flow Metab. 2019;39(11):2172\u201380.","journal-title":"J Cereb Blood Flow Metab"},{"key":"790_CR24","doi-asserted-by":"publisher","DOI":"10.1177\/0271678X19887781","author":"C Salinas","year":"2019","unstructured":"Salinas C, Lohith TG, Purohit A, Struyk A, Sur C, Bennacef I, et al. Test\u2013retest characteristic of [18F]MK-6240 quantitative outcomes in cognitively normal adults and subjects with Alzheimer\u2019s disease. J Cereb Blood Flow Metab. 2019. https:\/\/doi.org\/10.1177\/0271678X19887781.","journal-title":"J Cereb Blood Flow Metab"},{"issue":"10","key":"790_CR25","doi-asserted-by":"publisher","first-page":"1629","DOI":"10.1007\/s00259-009-1129-6","volume":"36","author":"N Tolboom","year":"2009","unstructured":"Tolboom N, Yaqub M, Boellaard R, Luurtsema G, Windhorst AD, Scheltens P, et al. Test-retest variability of quantitative [11C]PIB studies in Alzheimer\u2019s disease. Eur J Nucl Med Mol Imaging. 2009;36(10):1629\u201338.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"3","key":"790_CR26","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1177\/0271678X16644463","volume":"37","author":"I Lopes Alves","year":"2017","unstructured":"Lopes Alves I, Willemsen AT, Dierckx RA, da Silva AMM, Koole M. Dual time-point imaging for post-dose binding potential estimation applied to a [11C]raclopride PET dose occupancy study. J Cereb Blood Flow Metab Off J Int Soc Cereb Blood Flow Metab. 2017;37(3):866\u201376.","journal-title":"J Cereb Blood Flow Metab Off J Int Soc Cereb Blood Flow Metab"},{"issue":"7","key":"790_CR27","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.2967\/jnumed.117.200964","volume":"59","author":"S Bullich","year":"2018","unstructured":"Bullich S, Barthel H, Koglin N, Becker GA, Santi SD, Jovalekic A, et al. Validation of noninvasive tracer kinetic analysis of 18F-florbetaben PET using a dual\u2013time-window acquisition protocol. J Nucl Med. 2018;59(7):1104\u201310.","journal-title":"J Nucl Med"},{"issue":"2","key":"790_CR28","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1177\/0271678X18770107","volume":"39","author":"M N\u00f8rgaard","year":"2019","unstructured":"N\u00f8rgaard M, Ganz M, Svarer C, Feng L, Ichise M, Lanzenberger R, et al. Cerebral serotonin transporter measurements with [11C]DASB: a review on acquisition and preprocessing across 21 PET centres. J Cereb Blood Flow Metab. 2019;39(2):210\u201322.","journal-title":"J Cereb Blood Flow Metab"}],"container-title":["EJNMMI Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13550-021-00790-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13550-021-00790-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13550-021-00790-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,27]],"date-time":"2021-05-27T20:18:27Z","timestamp":1622146707000},"score":1,"resource":{"primary":{"URL":"https:\/\/ejnmmires.springeropen.com\/articles\/10.1186\/s13550-021-00790-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,27]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["790"],"URL":"https:\/\/doi.org\/10.1186\/s13550-021-00790-x","relation":{},"ISSN":["2191-219X"],"issn-type":[{"value":"2191-219X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,27]]},"assertion":[{"value":"23 November 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 May 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 May 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was conducted at the University Hospital Leuven, Belgium, and approved by the local Ethics Committee (University Hospitals Leuven\/KU Leuven, ClinicalTrials.gov no. NCT02562989). The subjects (or legal representative) gave written informed consent before enrollment in the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors consent for publication and all subjects enrolled in the study agreed for their data to be used for further analyses.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"TGL, EDH, CS, and AS are or were employees of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Kenilworth, NJ USA, at the time of the study and may own stock and\/or hold stock options in the Company.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"49"}}